Equillium Results Presentation Deck

EQUALISE Type B Summary: 13 subjects dosed Database cut on September 2, 2022, analysis includes: 13 subjects enrolled and dosed (Safety Population) 12 subjects have received > 1 dose and a post-baseline assessment (Efficacy Population) 1 subject discontinued without a post-baseline efficacy assessment due to unrelated adverse event after 1 dose ● · 10 6 subjects assessed at 28 weeks / EOS @ 11 subjects assessed at 12 weeks Patients are highly proteinuric: baseline UPCR mean of 5.8 g/g Range 1.1 to 16.5 g/g equillium Based on interim data from 2 Sep 2022-subject to change: Abbreviations: UPCR urine protein creatinine ratio; EOS end of study: hr hour 23

View entire presentation